How to access Cyltezo (Humira biosimilar) from the UAE: 2026 pathway via CCAD, Tawam, and private specialty clinics | Reserve Meds

Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.

The UAE treats large adalimumab populations across rheumatology, dermatology, gastroenterology, and ophthalmology at CCAD, Tawam, Burjeel Medical City, American Hospital Dubai, Mediclinic City, Saudi German, and others. The 2026 question for Humira patients is whether to switch to Cyltezo, the FDA interchangeable biosimilar.

Why Cyltezo, why now

Cyltezo (adalimumab-adbm) is a Boehringer Ingelheim biosimilar of the reference biologic Humira (adalimumab). The US FDA approved Cyltezo in August 2017 and granted interchangeability designation in October 2021, making it the first interchangeable adalimumab biosimilar in the United States. Cyltezo carries the same indications as reference Humira: rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis aged 4 and older, ankylosing spondylitis (AS), psoriatic arthritis (PsA), moderate-to-severe plaque psoriasis (adults and paediatric aged 6 and older), Crohn's disease (adults and paediatric aged 6 and older), ulcerative colitis (adults and paediatric aged 5 and older), hidradenitis suppurativa (adults and paediatric aged 12 and older), and non-infectious uveitis. Standard dosing is 40 mg subcutaneously every other week after loading, varying by indication and patient weight.

The 2026 question for a UAE patient on Humira is whether to switch to Cyltezo, which has the same molecular activity. The UAE has multi-emirate specialty depth: CCAD, Tawam, SKMC, Burjeel Medical City, Mediclinic City, American Hospital Dubai, King's College Hospital Dubai, and Al Jalila Children's Specialty Hospital all maintain mature TNF-biologic prescribing services. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic. Other US-approved Humira biosimilars include Amjevita, Hyrimoz, Hadlima, Yusimry, Abrilada, Hulio, Idacio, Yuflyma, and others.

What Cyltezo is, in plain language

Cyltezo is a subcutaneous adalimumab biosimilar supplied as a prefilled pen or prefilled syringe. After clinic-supervised training, the patient self-administers at home every other week. Onset of clinical effect is gradual, typically with partial response by week 4 and fuller response by week 12 to 24 depending on indication. Cyltezo is interchangeable with Humira per FDA designation, meaning the molecular activity is clinically equivalent. Reference Humira and several adalimumab biosimilars are already EDE-registered in the UAE; Cyltezo's EDE registration status is variable.

Access pathway in the UAE

The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance for the entire UAE. The Department of Health Abu Dhabi (DoH Abu Dhabi), the Dubai Health Authority (DHA), and MOHAP for the Northern Emirates govern healthcare facility licensing. Where Cyltezo is not yet EDE-registered, access runs through an EDE-approved named-patient personal-import authorisation, with the relevant emirate-level health authority acknowledgment, filed by the treating specialist at CCAD, Tawam, SKMC, Burjeel Medical City, American Hospital Dubai, Mediclinic City, King's College, or one of the other licensed specialty centres.

The treating physician submits a named-patient import application documenting the indication, prior treatment history, hepatitis B and TB screening results, and the requested dose and shipment quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Cyltezo from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree, and ships under validated cold chain to Abu Dhabi or Dubai International Airport.

Eligibility at a UAE specialty clinic

The treating specialist confirms the indication, screens for chronic hepatitis B (HBsAg, anti-HBc, HBV DNA if reactive), latent TB (QuantiFERON IGRA or Mantoux plus chest radiograph), and active infection. Vaccination status is reviewed and any live vaccines updated before initiation. Pregnancy plans are documented for women of childbearing potential. Heart failure status is assessed (NYHA Class III or IV is a contraindication). Paediatric cases are typically managed at Tawam, CCAD, or Al Jalila Children's Specialty Hospital.

Documentation required

The patient and physician should be prepared to provide: a current Emirates ID or passport; the specialist's diagnostic file confirming the indication; documentation of prior therapy and response, where applicable; recent hepatitis B serology and TB screening results; recent complete blood count, liver function, renal function; the treating physician's prescription on hospital letterhead; the clinical justification letter; the EDE named-patient import application; the emirate-level health authority acknowledgment (DoH Abu Dhabi, DHA, or MOHAP); and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US export documentation, manufacturer pedigree, and customs packet.

Costs and funding considerations

Medicine price: quote on request. You get a written quote for your case before you commit. Thiqa coverage for Emirati nationals applies under the chronic-disease formulary once eligibility is confirmed. DHA Saada for Emirati nationals in Dubai covers similarly. Daman Enhanced, Daman Premier, AXA Gulf, Allianz, MetLife, BUPA Arabia, NEXtCARE, and Oman Insurance plans active across the UAE increasingly favour adalimumab biosimilars on UM grounds and generally cover with pre-authorisation. Reserve Meds will help structure the insurer or government-payor submission.

Typical timeline

Weeks 0 to 2: confirm indication, complete hepatitis B and TB screening, prescription preparation, EDE filing. Weeks 2 to 4: shipment arrival at Abu Dhabi or Dubai International Airport, clinic-supervised injection one to two sessions, patient or caregiver training. Weeks 4 to 12: every-other-week SC at home; partial response by week 4, fuller response by week 12 depending on indication. Months 6 and 12: full reassessment using indication-specific disease activity scores.

When Cyltezo is the wrong drug

Active untreated tuberculosis or hepatitis B reactivation risk must be treated first; TNF inhibition is contraindicated until that is addressed. NYHA Class III or IV heart failure is a contraindication. Demyelinating disease is a relative contraindication. Active malignancy other than non-melanoma skin cancer is a contraindication. Patients with documented non-response to adalimumab or with neutralising anti-drug antibodies should be considered for an alternative TNF or a different mechanism class rather than another adalimumab biosimilar. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic.

Frequently asked questions

• Is the pathway legal in the UAE? Yes. It operates under EDE named-patient personal-import authorisation with emirate-level health authority acknowledgment.
• Will Thiqa, DHA Saada, or my insurance cover Cyltezo? Emirati nationals may secure Thiqa or DHA Saada chronic-disease coverage; private insurance pre-authorisation is generally available where indication is documented.
• Is the molecular activity the same as Humira? Yes; FDA interchangeability designation confirms clinical equivalence with the reference biologic.
• How is Cyltezo shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Abu Dhabi or Dubai International Airport.
• Can my child use Cyltezo? Cyltezo is FDA-approved for paediatric patients across multiple indications. Paediatric cases are typically managed at Tawam, CCAD, or Al Jalila Children's Specialty Hospital.
• What if Cyltezo is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.

Closing

Reserve Meds runs the Cyltezo supply file from CCAD, Tawam, SKMC, Burjeel, American Hospital Dubai, Mediclinic City, or other UAE specialty referral through EDE registration or named-patient pathway and delivered cold-chain supply. Clinical decisions remain with your treating specialist. To open a case, start your file in the patient portal or message us on WhatsApp; we will send a written quote for your case.

Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice.